Research Projects

Dr. Chavis
(PI) A Non-Treatment Study of Risk Factors for Nonarteritic Anterior Ischemic Optic Neuropathy
NAION
Project Dates: 09/01/08 - 09/01/12

Dr. Ablonczy
(PI) The Mechanism of the Outer Blood Retina-Barrier Breakdown
NIH/NEI
Project Dates: 09/30/10 - 06/30/15

Dr. Crosson
(PI) Protein Acetylation in Glaucomatous Optic Neuropathy
NIH/NEI
Project Dates: 01/01/11 - 12/31/14

(PI) Reversal of RPE Dysfunction Alimera Compounds
Alimera Sciences
Project Dates: 10/06/11 - 04/30/13

(PI) SmartState SC Center of Economic Excellence in Vision Science
SC Research Centers of Economic Excellence
Project Dates: 06/29/05 - 06/30/12

(PI) SmartState Center for Vision Science Research
MUSC Fdn.
Project Dates: 07/01/11 - 06/30/12

Dr. Del Priore
(PI) 2012 Unrestricted RPB Grant
Research to Prevent Blindness
Project Dates: 01/01/99 - 12/31/12

(PI) Greater NY Regional Research Center for the Study of Retinal Degenerative Diseases
Fdn. Fighting Blindness
Project Dates: 10/01/11 - 06/30/15

Dr. Evans
(Co-I) Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1% / Brimonidine 0.2%
Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients with Open-
Angle Glaucoma and/or Ocular Hypertension
PI: Matthew Nutaitis
Sponsor: MUSC OIP
Dept: Ophthalmology Award: C-10-003 (11041486-2)

Dr. Husain
(PI) Opioidergic System: Its Role(s) in Glaucoma
NIH/NEI
Project Dates: 09/01/10 - 05/31/14

Dr. Koutalos
(PI) Transport Processes in Photoreceptors
NIH/NEI
Project Dates: 07/01/03 - 02/28/13

Dr. Kylstra
(PI) 12-Month, Multi-Center, 2-Stage (Open-Label, Dose-Escalation, Followed by Masked, Randomized)
Single-Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME)
Associated with Retinal Vein Occlusion (RVO)
Allergan, Inc.
Project Dates: 07/14/11 - 06/30/14

Dr. Nutaitis
(PI) Three Month Efficacy and Safety Study of a Fixed Combination of Brinzolamide 1% / Brimonidine 0.2%
Compared to Brinzolamide 1% and Brimonidine 0.2% All Dosed Three Times Daily in Patients with Open-
Angle Glaucoma and/or Ocular Hypertension
Project Dates: 06/01/11 - 05/31/12

(PI) Long-Term, Safety, Follow-up for Subjects Previously Implanted with the AcrySof Cachet Phakic Lens in
Clinical Studies C-02-23, C-02-40, C-03-21 and C-05-57
Alcon, Inc.
Project Dates: 02/01/12 - 01/01/13

Dr. Patel
(Co-I)12-Month, Multi-Center, 2-Stage (Open-Label, Dose-Escalation, Followed by Masked, Randomized) Single-
Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with
Retinal Vein Occlusion (RVO)
PI: Jan Kylstra
Allergan, Inc.
Dept: Ophthalmology Award: 208397-001 (12010102-1)

(Co-I) 12-Month, Multi-Center, 2-Stage (Open-Label, Dose-Escalation, Followed by Masked, Randomized) Single-
Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with
Retinal Vein Occlusion (RVO)
PI: Jan Kylstra
Allergan, Inc.
Dept: Ophthalmology Award: 208397-001 (12010102-2)

Dr. Rohrer
(PI) Alternative Pathway of Complement Activation in Age-Related Macular Degeneration
NIH/NEI
Project Dates: 07/01/10 - 06/30/15

(PI) Neurotrophic Factors and Retinal Degeneration
Fdn. Fighting Blindness
Project Dates: 08/01/09 - 12/31/12

(PI) Complement Factor H Haplotypes and Smoking in Age-Related Macular Degeneration
VAMC
Project Dates: 10/01/10 - 09/30/14

(PI) Complement and AMD
Alexion Pharmaceuticals
Project Dates: 12/20/11 - 12/19/12

(PI) Testing Compounds that Target Mitochondrial Metabolism
MitoChem Therapeutics
Project Dates: 06/01/12 - 05/31/13

(PI) High Content Metabolic Screens for Anti-Degenerative Agents
Fdn. Fighting Blindness
Project Dates: 06/01/08 - 05/31/13

Dr. Wilson
(PI) Infant Aphakia Treatment Study (IATS)
Emory Univ.
Project Dates: 06/01/11 - 05/31/12

(PI) Protocol # 670, A Randomized, Multi-Center, Double-Masked, Parallel-Group Study Assessing the Safety
and Efficacy of Loteprednol Etabonate Ophthalmic Gel, 0.5% versus Prednisolone Acetate Ophthalmic S
Bausch and Lomb
Project Dates: 03/15/12 - 05/01/13

PI, Principal Investigator
Co-PI, Co-Principal Investigator
Co-I, Co-Investigator

Top of Page